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BakPreviously we have shown that interferon (IFN)-α induced apoptosis is predominantly mediated by the
upregulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) via the caspase-8 pathway.
It was also shown that recruitment of mitochondria in IFN-α induced apoptosis involves the cleavage of
BH3 interacting domain death agonist (Bid) to truncated Bid (tBid). In the present study, we demonstrate
that tBid induced by IFN-α2a activates mitochondrial Bak to trigger the loss of mitochondrial membrane
integrity, consequently causing release of apoptosis-inducing factor (AIF) in ovarian cancer cells, OVCAR3.
AIF translocates from the mitochondria to the nucleus and induces nuclear fragmentation and cell death.
Both a small molecule Bid inhibitor (BI-6C9) or Bid-RNA interference (RNAi) preserved mitochondrial mem-
brane potential, prevented nuclear translocation of AIF, and abrogated IFN-α2a-induced cell death. Cell death
induced by tBid was inhibited by AIF-RNAi, indicating that caspase-independent AIF signaling is the main
pathway through which Bid mediates cell death. This was further supported by experiments showing that
BI-6C9 did not prevent the release of cytochrome c from mitochondria to cytosol, while the release of AIF
was prevented. In conclusion, IFN-α2a-induced apoptosis is mediated via the mitochondria-associated path-
way involving the cleavage of Bid followed by AIF release that involves Bak activation and translocation of AIF
from the mitochondria to the nucleus in OVCAR3 cells.
Published by Elsevier B.V.1. Introduction
Interferons (IFNs) are members of a family of cytokines that have
antiviral, antiproliferative, and immunomodulatory properties [1].
There are several types of IFNs, each of which interacts with a type-
speciﬁc receptor complex. Type I IFNs, which include IFN-α, IFN-β,
and IFN-ϖ, are ubiquitously induced in mammals by viruses and
other factors, (e.g. dsRNA) and interact with the IFN-α receptor
(IFNAR) subunits 1 and 2 [2]. Activated T lymphocytes and NK cells
produce the single species of type II IFN (IFN-γ), which interacts
with the IFN-γ receptor (IFNGR) subunits 1 and 2. Nearly every cell
type expresses receptors for type I IFNs and IFN-γ [3–5]. The recently
characterized type III IFNs include IFN-λ1 (IL-29), IFN-λ2 (IL‐28A),g domain death agonist; AIF,
rogrammed cell death; EndoG,
D, Fas-associated death domain;
tease-activating factor-1; MTT,
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al membrane potential; BMH,
rch, National Institute of Allergy
33Rm2N09G.2, 33NorthDrive,
1 301 402 0166.
.V.and IFN-λ3 (IL-28B), which bind to the IFN-λ receptor (IFNLR1) and
the IL-10Rβ subunit (IL-10Rβ). All IFNs exhibit species speciﬁcity
[2,6].
The clinical applications of IFN-α are treatment of viral infections
such as hepatitis B and C, and treatment of certain malignancies such
as malignant melanoma, hairy cell leukemia, Kaposi sarcoma, chronic
myelogenous leukemia and renal cell carcinoma (in combination
with Avastin). IFN-β has been used in the treatment of relapsing–
remitting multiple sclerosis [3]. In contrast, IFN-γ is the sole type 2
IFN, and is predominantly produced by T helper cell type 1 lympho-
cytes and natural killer cells. IFN-γ is used clinically for the treatment
of chronic granulomatous disease and congenital osteopetrosis, but it
has been generally unsuccessful as an antitumor agent [3].
Apoptosis, a form of programmed cell death (PCD), is an essential
process for both development and maintenance of tissue homeostasis
and was ﬁrst recognized by Kerr et al. [7] It has been well established
that apoptosis in most cells is induced through the activation of either
mitochondrial (intrinsic) pathway or death receptor (extrinsic) path-
way [8,9]. Both ways lead to cell shrinkage, membrane blebbing, chro-
matin condensation and formation of apoptotic bodies [10]. Apoptotic
cell death largely proceeds in either a caspase-dependent or caspase-
independent manner [11]. Several studies provide evidence that, in
response to apoptotic stimuli, mitochondria can release caspase-
independent cell death effectors such as cytochrome c, Apoptosis-
Inducing Factor (AIF) and endonuclease G (EndoG) [11,12].
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caspase-8, is activated in the Fas/Apo-1 (CD95), tumor necrosis factor
(TNF)-α, and tumor necrosis factor related apoptosis-inducing ligand
(TRAIL) receptor-mediated cell death [13,14]. Once Bid is cleaved and
activated, it is translocated to the mitochondria as tBid and induces
the release of proapoptotic proteins such as cytochrome c, AIF and
EndoG [13,15]. The ability of Bid to induce release of cytochrome c,
AIF or EndoG is mediated by the proapoptotic Bcl-2 family proteins
Bak or Bax, because Bid can facilitate the insertion of Bak or Bax into
the mitochondrial membrane to form functional oligomers [15–17].
Double-knockout mouse embryonic ﬁbroblasts (MEFs) (Bak−/−
and Bax−/−) are resistant to apoptosis by various agents, and mice
deﬁcient in both Bak and Bax survived anti-Fas antibody treatment
[17]. There is increasing evidence to suggest the involvement of Bak
and Bax in the release of cytochrome c, and it was reported that muta-
tions in the Bax or Bak gene render cells resistant to apoptosis [18].
Type I IFNs have potent proapoptotic activities in cell lines rep-
resenting various histologic origins, suggesting that the induction of
apoptosis is important to their overall physiological functions. IFNs
induce apoptosis indirectly by upregulating the expression of death
ligands, such as TRAIL and Fas ligand, which activate the extrinsic
Fas-associated death domain (FADD)/Caspase-8 signaling pathway
[19–21]. IFNs can also modulate mitochondrial outer membrane sta-
bility, in part, by activating proapoptotic Bcl-2 members Bak and
Bax [22]. This leads to release of proapoptotic proteins such as cyto-
chrome c, AIF and EndoG and ﬁnally results in depolarization of the
inner mitochondrial membrane [23]. Pretreatment with type I IFNs
can also sensitize cells to the proapoptotic effects of other therapeu-
tics [24]. Although IFN-induced apoptosis is caspase-dependent
and involves the mitochondria, the identities of all of the mediators
responsible for disruption of the mitochondria during this process
are still unknown [25].
In the present study, we investigated IFN-α2a induced apoptotic
signaling in ovarian cancer cells (OVCAR3). We found that IFN-α2a in-
duced apoptosis is mediated via the mitochondria-associated pathway
involving the cleavage of Bid followed by AIF release that involves Bak
activation and translocation of AIF from themitochondria to the nucleus
in OVCAR3 cells.
2. Material and methods
2.1. Cell and reagents
OVCAR3 cells were cultured in RPMI 1640 complete medium
(Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum, 2 mM L-glutamine, 100 units/ml
penicillin, and 100 mg/ml streptomycin at 37 °C in a humidiﬁed 5% CO2
incubator. IFN-α2a was obtained from Hoffman La Roche (Nutley, NJ).
The Bid inhibitor BI-6C9 and the inhibitor of apoptosome formation
NS3694 were obtained from (Sigma-Aldrich, St Louis, MO). Antibodies
purchased were as follows: rabbit polyclonal anti-Bid, caspase-3,
caspase-9, poly ADP-ribose polymerase (PARP). apoptotic protease-
activating factor-1 (Apaf-1), EndoG, AIF and β-actin (Cell Signaling,
Danvers, MA); mouse anti‐caspase-8, cytochrome c and Heat shock pro-
tein 60 (Hsp60) (BDBiosciences, San Jose, CA); rabbit polyclonal anti-Bax
(Millipore, Temecula, CA) and rabbit polyclonal anti-Bak (Epitomics, Inc.,
Burlingame, CA); rabbit polyclonal anti-Lamin B1 (Abcam, Cambridge,
MA).
2.2. Antiproliferative assay
6×103 OVCAR3 cells pre well were seeded in 96-well plate and in-
cubated for 24 h. IFN-α2a was then added for an additional 72 h and
cell viability was evaluated using 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl‐2H-tetrazolium bromide (MTT) as described previously
[26]. Brieﬂy, after treatment as indicated, followed by incubationwith MTT (Sigma-Aldrich) for 4 h, the stained living cells were solubi-
lized with acidiﬁed isopropanol (0.04 N HCI in isopropanol) and the
absorbance was measured at 570 nm. Experiments were carried out
in triplicate in duplicate plates.
2.3. RNA interference
OVCAR3 cells (1.5×106 in 10 cm dish or 6×103/well in 96-well
plate) were seeded and incubated for 24 h in antibiotic-free RPMI
1640 containing 10% FBS and 2 mM L-glutamine. After incubation
for 24 h, cells were transfected with 20 nM RNA interference (RNAi)
oligos complexed in Lipofectamine 2000 (Invitrogen) in Opti-MEM
media (Invitrogen) for 24 h. IFN was then added for an additional
24 h. The media was then removed and replaced with RPMI 1640
containing 2% FBS, 2 mM L-glutamine, 50 U/ml penicillin G and
50 mg/ml streptomycin. To determine efﬁciency of RNAi-mediated
gene silencing, cells were harvested and lysates were prepared and
analyzed, as described for Western blot analysis. RNAi oligo purchased
were as follows: Bid (Oligo ID: 141377 and 141378); Bax (141354
and 141355); Bak (184085 and 184087); Apaf-1 (141235); Cytochrome
c (147625); Caspase-9 (189012); AIF (113512 and 113513) from Invi-
trogen: Apaf-1 (J003456-13); Cytochrome c (J017355-06); Caspase-9
(J003309-05); ENDOG (J004426-08 and J004426-09) from Thermo
Fisher Scientiﬁc Dharmacon (Lafayette, CO).
2.4. Plasmid and transfection
The plasmid pDsRed2-Bid for expression of DsRed fused to the
C-terminus of Bid to allow translocation analyses of full-length Bid
and tBid was purchased commercially (Clontech Laboratories, Inc.,
Mountain View, CA). Plasmid transfections of 3×105 OVCAR3 cells
seeded in 6-well plates were performed in antibiotic-free growth me-
dium using FuGENE HD (Roche Diagnostic Corporation; Indianapolis,
IN). Controls were treated with 100 μl/ml OPTI-MEM only and vehicle
controls with 3 μl/ml FuGENE HD.
2.5. Western blot analysis
Cells were harvested as indicated, lysed in mammalian protein ex-
traction (M-PER) reagent lysis buffer (Pierce Chemical, Rockford, IL)
containing Halt protease inhibitor and Halt phosphatase inhibitor
mixtures (Thermo Fisher Scientiﬁc, Waltham, MA) for 1 hour on ice.
Protein concentrations were determined by measuring the absor-
bance at 280 nm, using a Nanodrop spectrophotometer (Nanodrop
Technologies, Wilmington, DE), and equal amounts of protein were
separated by SDS-PAGE using 10 to 20% Tris-glycine gels, (Invitrogen
Corp., Gaithersburg, MD) under reducing conditions, and transferred
to nitrocellulose membranes. Membranes were blocked with 5% fat-
free milk in PBS containing 0.05% Tween 20 for 1 h and incubated
with each antibody overnight at 4 °C. Secondary goat anti-mouse
and goat anti-rabbit Abs were purchased from Southern Biotechnology
Associates (Birmingham, AL). Membranes were developed using the
SuperSignal West Femto ECL kit (Thermo Fisher Scientiﬁc) and
visualized with an LAS-3000 charge-coupled device camera system
(Fujiﬁlm Medical System, Stamford, CT).
2.6. Immunostaining and confocal laser scanning microscopy
For immunoﬂuorescence analysis, OVCAR3 cells were seeded in
6-well plates at a density of 2×104cells/well. Mitochondria were sta-
ined with MitoTracker (Invitrogen) according to the manufacturer's
protocol or visualized by CellLight Reagents BacMam 2.0 (Invitrogen).
After treatment, cells were ﬁxed with 4% paraformaldehyde (PFA).
The cells were permeabilized by exposure for 30 min to 0.1% Triton
X-100, and were then placed in blocking solution (3% horse serum)
for 30 min. Cells were then exposed to each antibody overnight at
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labeled goat anti-rabbit IgG for 30 min at RT in the dark. The speci-
ﬁcity immunoreactivity was controlled by omission of the primary
antibody. Nuclei were counterstained with DAPI (Invitrogen). Images
of stained cells were obtained by confocal microscopy (Leica SP5,
Leica Microsystems, Exton, PA). All data were processed with Leica
LAS AF software (Version 2.2.1, Leica Microsystems).
2.7. Flow cytometry for cell death and mitochondrial membrane
potential (ΔΨm) measurements
Phosphatidylserine exposure on the outer layer of the plasma
membrane was detected using the MEHBCYTO Apoptosis Kit (MBL,
Nagoya, Japan) according to the manufacturer's instructions. In
brief, 2×105 cells were pelleted following treatment and washed in
PBS (pH 7.4). Next, the cells were resuspended in 100 μl of binding
buffer containing annexin V-FITC and propidium iodide (PI) for
15 min at RT in the dark. Prior to ﬂow cytometry analysis, 400 μl of
binding buffer were added to the cells.c
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Fig. 1. Bid inhibition protects OVCAR3 cells against IFN-α2a-induced apoptosis (a–b). Bid
determined by antiproliferative assay. (c) Cleavage of caspases, PARP and Bid were assesse
apoptotic population after treatment of IFN-α2a with BI-6C9 or Bid-RNAi for 24 and 72 h.
early apoptotic (lower right), late apoptotic (upper right), and necrotic (upper left). Num
with no treatment. Lanes: (c) 1, No treatment; 2, IFN-α2a: 1 ng/ml; 3, IFN-α2a: 10 ng/ml;For ΔΨm determination, Mitochondrial Membrane Potential
Detection Kit (Stratagene, La Jolla, CA, USA) was used according to
the manufacturer's instructions. Brieﬂy, 1×106 cells were pelleted
following treatment, resuspended in 500 μl of 1× JC-1 reagent and
incubated in a humidiﬁed 5% CO2 incubator at 37 °C for 15 min.
Next, cells were pelleted and washed in 2 ml of 1× assay buffer.
This step was repeated.
Finally, cells were pelleted, resuspended in 1× assay buffer, and
analyzed by ﬂow cytometry. Analysis was performed using FlowJo
software (Tree Star, Ashland, OR).
2.8. Determination of Bax and Bak oligomerization and activation
For detection of Bax and Bak oligomerization, 1×106 cells were
harvested, washed, and resuspended in 80 μl of 100 mM EDTA/PBS
(pH7.4), incubatedwith 1 mMcross-linking agent bismaleimidohexane
(BMH) for 30 min at room temperature, quenched with 100 mM
dithiothreitol (Sigma-Aldrich) for 15 min, pelleted, and processed for
Western blotting.1.5
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cells were washed in PBS (pH 7.4) and ﬁxed in 400 μl of 0.25% para-
formaldehyde for 5 min, subsequently washed two times with
2% FBS in PBS (pH 7.4), and incubated in 50 μl of staining buffer (2%
FBS and 100 μg/ml digitonin in PBS (pH 7.4)) with a conformation-
speciﬁc mouse monoclonal antibody against Bax and Bak for 30 min
at room temperature. Then, cells were washed and resuspended in
50 μl of staining buffer containing 0.25 μg Alexa Fluor 488-labeled
goat anti-rabbit IgG for 30 min in the dark. Cells were washed again
and analyzed by ﬂow cytometry. Analysis and histogram overlays
were performed using FlowJo software.
2.9. Mitochondria and nuclei isolation
Mitochondria were isolated using the Qproteome Mitochondrial
Isolation Kit (Qiagen, Valencia, CA, USA) following the manufacturer's
instructions. Brieﬂy, 2×107 cells were washed in ice-cold PBS (pH
7.4) and incubated in lysis buffer with protease inhibitor (supplied
with the kit) for 10 min on an orbital shaker at 4 °C. Samples were cen-
trifuged for 10 min at 1000 g at 4 °C, and the pellet was resuspended in
a disruption buffer with protease inhibitor (supplied with the kit). Cells
were disrupted on ice by 10 rounds of aspiration and ejection through a
21-gauge needle. The lysate was centrifuged for 10 min at 1000 g at
4 °C, and the resulting supernatant was centrifuged at 6000 g at 4 °C
to pellet mitochondria. Mitochondria were washed with ice-cold4.8%
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Fig. 2. The Bid inhibition prevents IFN-α2a-induced mitochondrial depolarization. (a) OVCA
Bid-RNAi. Cells were collected and JC-1 was used to measure ΔΨm by ﬂow cytometry as desc
in the dot plots indicate the ratios of live cells and apoptotic cells, respectively (Live cells w
three times with essentially similar results. (b) BI-6C9 or Bid-RNAi prevented the accumulat
cytosol. Cells expressing a Bid-DsRed fusion protein and Mito-GFP show colocalization of m
pretreatment of BI-6C9 or Bid-RNAi for 24 h. Bid (red), mitochondria (green), nuclear stain
represents the merging of red and green.storage buffer (supplied with the kit) and centrifuged for 20 min at
6000 g at 4 °C. Cytoplasmic and nuclear proteins were isolated using
Qproteome nuclear protein kit (Qiagen) following the manufacturer's
instructions. Brieﬂy, 1×107 cells were harvested and lysed in lysis buff-
er. Twenty-ﬁve microliters of detergent solution was added to the cell
suspension and then centrifuged. The supernatant was retained as the
cytosolic fraction. The remaining pellet was incubated with extraction
buffer by gentle agitation at 4 °C for 30 min and was then centrifuged.
The supernatant was retained as the nuclear fraction. Samples were
snap-frozen on dry ice and stored at−80 °C.
2.10. Statistical analysis
Statistical comparisons of mean values were done by one-way
ANOVA. Statistical analysis was performed using JMP version 8.0
(SAS Institute, Cary, NC, USA). A P value of less than 0.05 was consid-
ered to be statistically signiﬁcant.
3. Results
3.1. Bid inhibition attenuates growth-inhibiting effect of IFN-α2a and
inhibits IFN-α2a-induced apoptosis
To examinewhether Bid inhibition attenuates the growth-inhibiting
effect of IFN-α2a in OVCAR3 cells, an antiproliferative assay wasBid DAPI mergedMito-GFP
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Bid-RNAi for 24 h. Bax or Bak (both green), mitochondria (red), nuclear staining (DAPI, blue), and merge of the three patterns are shown. IFN-α2a treated cells show translocation
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growth-inhibiting effect of IFN-α2a [14]. In addition to the RNAi
approach, the speciﬁc Bid inhibitor BI-6C9was applied to conﬁrm the es-
sential role of Bid in the growth-inhibiting effect by IFN-α2a. After cells
were incubated with Bid-RNAi or speciﬁc Bid inhibitor BI-6C9 at 37 °C
for 24 h, IFN-α2a was added at the concentration of 1, or 10 ng/ml,
followed by incubation for 72 h. As shown in Fig. 1a and b, Bid-RNAi or
BI-6C9 signiﬁcantly reduced the growth-inhibiting effect of IFN-α2a
(Supplementary Fig. 1, BID-RNAi in the absence of IFN-α2a).
Western blot analyses for Bid, caspase-3, -8, -9, and PARP were
carried out to determine whether IFN-α2a-induced apoptosis
through cleavage of Bid, caspase-3, -8, -9, and PARP. As shown in
Fig. 1c, western blot analysis revealed that Bid had been cleaved to
tBid after incubation with IFN-α2a, conﬁrming our previous results
[14]. Similarly, cleavage of caspase-3, -8, -9, and PARP, which are
mediators of apoptosis, were observed after treatment with IFN-
α2a. Bid-RNAi inhibited cleavage of Bid, however BI-6C9 did not,
which is consistent with the mechanism of BI-6C9 [27].
Flow cytometry analysis by annexin V-FITC and PI staining
showed that Bid inhibition drastically reduced IFN-α2a induced apo-
ptosis at both 24 and 72 h. As shown in Fig. 1d, apoptosis was seen in
28.1% of the cells at 24 h, 44.9% at 72 h with IFN-α2a and DMSO,
29.4% at 24 h, 43.7% at 72 h with IFN-α2a and negative RNAi, 9.8%
at 24 h, 16.5% at 72 h with IFN-α2a and BI-6C9 and 12.7% at 24 h,
17.9% at 72 h with IFN-α2a and Bid-RNAi.
3.2. IFN-α2a induces Bid-dependent ΔΨm depolarization
We next examined whether IFN-α2a induces Bid-dependent ΔΨm
depolarization. As shown in Fig. 2a, IFN-α2a treatment caused a sig-
niﬁcant loss of mitochondrial membrane potential. The Bid inhibition
with BI-6C9 or Bid-RNAi (shown previously [14]) signiﬁcantly pre-
vented IFN-α2a-induced breakdown of the mitochondrial membrane
potential, suggesting that Bid inhibition signiﬁcantly prevented Bid
translocation to the mitochondria and consequently prevented IFN-
α2a-induced collapse of the mitochondrial membrane potential in
OVCAR3 cells [14].
In addition, prevention of Bid translocation to the mitochondria
was conﬁrmed by immunostaining with confocal laser scanning mi-
croscopy. Bid inhibition-related reduction of IFN-α2a cytotoxicity
was associated with a lack of Bid translocation to the mitochondria
in experiments using pDsRed2-Bid vector and Mitotracker Green
staining. Bid translocation to the mitochondria cause the merging of
DsRed2-Bid and Mitotracker Green color, resulting in appearance of
yellow/orange. As shown in Fig. 2b, Bid translocation to the mito-
chondria was prevented with BI-6C9 or Bid-RNAi, indicating that
Bid translocation is essential for IFN-α2a induced apoptosis.
3.3. IFN-α2a-induced apoptosis is accompanied by Bak oligomerization
We then examined the extent to which Bax and Bak had under-
gone oligomerization in response to IFN-α2a, using two different
techniques. We ﬁrst investigated whether Bax and Bak underwent
oligomerization using the cross-linking agent BMH. As shown in
Fig. 3a, cross-linked Bak protein complexes were observed in
OVCAR3 cells treated with 10 ng/ml of IFN-α2a for 24 h, however,
cross-linked Bax protein complexes were not. Bak oligomerization
was prevented with BI-6C9. This result was conﬁrmed with an active
conformation-speciﬁc monoclonal Bak antibody and ﬂow cytometry
analysis in which activation causes a shift to the right of the resulting
histogram and bar graph valued histogram, as shown in Fig. 3b. These
ﬁndings were consistent with results obtained using immunostaining
with confocal laser scanning microscopy. As shown in Fig. 3c, IFN-α2a
treatment induced cross-linked Bak protein complexes, which was
prevented with BI-6C9 or Bid-RNAi.Furthermore, as shown in Fig. 3d, even though Bax‐RNAi knocked
down Bax and Bak‐RNAi knocked down Bak, only Bak-RNAi signiﬁ-
cantly attenuated IFN-α2a induced cytotoxicity in OVCAR3 cells
(Supplementary Fig. 2). Collectively, these ﬁndings suggest that IFN-
α2a-induced cytotoxicity is predominantly mediated by Bid translo-
cation to the mitochondria, which promote Bak controlled ΔΨm.
3.4. Apoptosome formation is not required for IFN-α2a-induced
Bid-mediated cell death
As shown in Fig. 4a–c, there were no signiﬁcant differences in cell
viability with IFN-α2a and the described gene-speciﬁc RNAi, although
each RNAi reduced its respective protein level. In the experiment with
the diarylurea compound, NS3694 which modulates apoptosome for-
mation, there was no signiﬁcant difference in cell viability as well
[28]. In addition, as shown in Fig. 4d, Flow cytometry analysis by
annexin V-FITC and PI staining showed that there were no signiﬁcant
difference in IFN-α2a-induced apoptosis with each apoptosome related
RNAi (Caspase-9, cytochrome c and Apaf-1) or NS3694.
These ﬁndings were conﬁrmed with immunostaining using confo-
cal laser scanning microscopy. As shown in Fig. 4e, IFN-α2a-induced
apoptosome formation, which was shown as areas of colocalization
in the merge panels as yellow. Apoptosome formation was prevented
with NS3694, while BI-6C9 did not inhibit apoptosome formation.
3.5. AIF functions as a major proapoptotic factor in the IFN-α2a-induced
Bid-mediated cell death through Bak oligomerization and activation
The potential role of a proapoptotic inducing protein in the execu-
tion of cell death downstream of Bid-mediated mitochondrial depo-
larization through Bak oligomerization, was further addressed by a
gene silencing approach. As shown in Fig. 5a–c, AIF-RNAi reduced
protein levels and signiﬁcantly attenuated IFN-α2a-induced cell
death in OVCAR3 cells, while cytochrome c-RNAi or EndoG-RNAi did
not (Supplementary Fig. 3). Flow cytometry analysis by annexin
V-FITC and PI staining showed that AIF-RNAi drastically reduced
IFN-α2a-induced apoptosis at both 24 and 72 h, while neither cyto-
chrome c nor EndoG-RNAi did not. As shown in Fig. 5d, apoptosis
was induced in 26.8% at 24 h, 48.4% at 72 h with IFN-α2a and nega-
tive RNAi, 12.6% at 24 h, 13.5% at 72 h with IFN-α2a and AIF-RNAi,
21.5% at 24 h, 42.5% at 72 h with IFN-α2a and cytochrome c-RNAi
and 20.1% at 24 h, 41.9% at 72 h with IFN-α2a and EndoG-RNAi.
These results suggested that AIF but not cytochrome c and EndoG is
responsible for IFN-α2a-induced Bid-mediated caspase-independent
execution of cell death.
3.6. Inhibition of Bid prevents the release of AIF from mitochondria by
IFN-α2a
Finally, we conﬁrmed the locations of AIF, cytochrome c and EndoG,
which are integral inner mitochondrial membrane proteins that are
often affected by mitochondrial transmembrane potential. Cells were
treatedwith IFN-α2a for 24 h, followed by isolation using theQproteome
cell compartment kit. As shown in Fig. 6a, AIF transferred frommitochon-
dria to the nucleus after exposure to 10 ng/ml IFN-α2a for 24 h and AIF
release from mitochondria to cytosol was inhibited with BI-6C9. Mean-
while, cytochrome c release was not inhibited with BI-6C9. EndoG
was not released from mitochondria with IFN-α2a treatment. Hsp60,
a mitochondria-associated protein, and lamin B1, a nuclear speciﬁc pro-
tein, were used to show the purity of the cellular fractions.
These ﬁndingswere conﬁrmedwith immunostaining using confocal
laser scanningmicroscopy. As shown in Fig. 6b–d, IFN-α2a-induced AIF
release from mitochondria to the nucleus, which was prevented with
BI-6C9 or Bid-RNAi. Unlike AIF, cytochrome c release was not inhibited
with BI-6C9 or Bid-RNAi. Consistent with the protein expression assay,
EndoG was not released.
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Fig. 5. AIF involves IFN-α2a-induced Bid-mediated cell death. The RNAi gene silencing of (a) AIF did reduced growth-inhibiting effect of IFN-α2a, whereas knockdown of (b) EndoG
or (c) cytochrome c did not. (d) Flow cytometry analysis of the apoptotic population after treatment of IFN-α2a with or without gene-speciﬁc RNAi for 24 and 72 h. Cells were
stained with Annexin V and PI. Quadrants are deﬁned as live (lower left), early apoptotic (lower right), late apoptotic (upper right), and necrotic (upper left). Numbers refer to
the percentage of cells in each quadrant. *pb0.05 in comparison with negative RNAi treatment.
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IFN-α is among the few cytokines to have an established role as an
effective antitumor agent in some malignant diseases, notably severalFig. 4. Apoptosome formation is not required in IFN-α2a-induced Bid‐mediated cell deat
respective RNAi was veriﬁed by immunoblot analysis. OVCAR3 cells transfected with Apaf-
(b) Apaf-1, cytochrome c or caspase-9 did not attenuate IFN-α2a-induced cell death as dete
not attenuate IFN-α2a-induced cell death as determined by antiproliferative assay. (d) Flo
without gene-speciﬁc RNAi for 24 and 72 h. Cells were stained with Annexin V and PI. Q
(upper right), and necrotic (upper left). Numbers refer to the percentage of cells in each qua
microscopy in OVCAR3 cells exposed to IFN-α2a for 24 h after pretreatment of BI-6C9 or NS3
merge of the three patterns are shown. IFN-α2a treated cells show colocalization of cytoch
meaning inhibition of apoptosome formation, while there was no signiﬁcant change of colo
negative RNAi 20 nM; 3, negative RNAi 100 nM; 4, target RNAi 20 nM; 5, target RNAi 100 nlymphoid malignancies [29]. The mechanism by which IFN exerts its
antitumor activity is still ill-deﬁned, but we and others have shown
that IFN can be a potent inducer of apoptosis in some malignant
cells, forming an attractive hypothesis for how it may act in cancerh. (a) Downregulation of Apaf-1, cytochrome c and caspase-9 protein levels by their
1, cytochrome c or caspase-9-RNAi were harvested and lysed for immunoblot analysis.
rmined by antiproliferative assay. (c) NS3694, inhibitor of apoptosome formation, did
w cytometry analysis of the apoptotic population after treatment of IFN-α2a with or
uadrants are deﬁned as live (lower left), early apoptotic (lower right), late apoptotic
drant. (e) Cytochrome c and casapase-9 release from mitochondria imaged by confocal
694 for 24 h. Cytochrome c (green), caspase-9 (red), nuclear staining (DAPI, blue), and
rome c and caspase-9. BI-6C9 decreased colocalization of cytochrome c and caspase-9,
calization of cytochrome c and caspase-9 with NS3694. Lanes: (a) 1, No treatment; 2,
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protocols where IFN has been combined with different cytostatic
agents [21,32,33]. IFN may be predicted to have a different mode of
activating the apoptosis machinery in comparison with chemothera-
py; this may explain the positive effects observed in such combina-
tion protocols.
The present study demonstrates a key role for the proapoptotic Bcl-2
family protein Bid in mitochondrial membrane permeabilization and
the subsequent nuclear translocation of AIF in OVCAR3 cells exposed
to IFN-α2a. IFN-α2a-induced translocation of Bid to mitochondria,
followed by mitochondrial membrane depolarization, Bak activation
and AIF release to the nucleus. The pharmacological Bid inhibitor
BI-6C9 and RNAi-mediated gene silencing, as shown previously bothsigniﬁcantly preventing mitochondrial Bid translocation, migration of
AIF to the nucleus, and, hence, IFN-α2a-induced cell death.
In order to optimize the use of IFN-α2a in the clinic, a better under-
standing of the molecular background to IFN-α2a-induced apoptosis
is warranted. This prompted us to deﬁne molecular events leading to
IFN-α-induced apoptosis. Our results show that IFN-α2a signiﬁcantly
disrupts the mitochondrial membrane potential (Fig. 2a), thus con-
ﬁrming previous work [14]. We thereby presume that mitochondria
play an important role in IFN-α-induced apoptosis. Bcl-2 proteins are
the main regulators of the mitochondrial-mediated death pathway by
either suppressing or promoting mitochondrial changes in regulating
the release of key proteins from mitochondria. The Bcl-2 family deter-
mines the cellular susceptibility of PCD [34]. How the Bcl-2 family
1387K. Miyake et al. / Biochimica et Biophysica Acta 1823 (2012) 1378–1388proteins control the release of mitochondrial proteins is still unclear.
However, it is clear that multidomain proapoptotic proteins such
as Bax and Bak participate in this process [35]. Bax activation or Bak
conformational changes lead to the formation of a mitochondrial pore
that facilitates the release of mitochondrial proapoptotic proteins.
Therefore, in apoptotic PCD, the combined genetic ablation of both
Bax and Bak confer resistance to apoptosis.
In the present study, upon treatment of IFN-α2a, Bak protein was
activated but not Bax (Fig. 3a–c), which suggested that Bak is necessary
in the action of IFN-α2a onOVCAR3 cells. It is very interesting that these
data well supported the hypothesis that Bax and Bak may perform dif-
ferent functions in different cell death models [36], although Bax and
Bak are similar in protein structure and have similar function in apopto-
sis [37]. However, the regulation of Bak and Bax activation is distinct, as
is probably their role in IFN-α2a-induced apoptosis. Using immuno-
staining with confocal laser scanning microscopy, we also demonstrat-
ed that Bak activation occurred in the apoptotic response, prior to the
AIF release and loss of ΔΨm, whereas Bax activation was not observed
(Fig. 3c). Cells can probably die in response to IFN-α2a without activat-
ing Bax since there was no signiﬁcant difference in the cell viability
assay with Bax-RNAi. Furthermore, small molecule Bid inhibitor BI-
6C9 or Bid-RNAi prevented the translocation of Bak to mitochondria,
but did not inﬂuence the translocation of Bax in Western blotting
assay (Fig. 3a) or ﬂow cytometric analysis (Fig. 3b), implying that
ﬂuctuations in Bax levels are of less importance. In order to delineate
the importance of Bak in IFN-α2a-induced apoptosis, it would have
been helpful to use Bak−/− ﬁbroblasts. However, in contrast to many
established tumor cell lines and primary tumor cells, normal mouse
embryo ﬁbroblasts are not sensitive to mouse IFN-induced apoptosis
and therefore these experiments cannot be preformed [22].
Another important aspect of the present study addresses the role
of AIF in mediating caspase-independent cell death downstream
of Bid activation through Bak activation. The Bak/AIF pathway is a
major caspase-independent apoptotic cascade [11,38]. AIF is a ﬂavo-
protein with both oxidoreductase and DNA-binding domains but no
intrinsic DNase activity [11,39,40]. AIF can promote cell survival or
induce apoptosis. In mitochondria, AIF is involved in cellular respira-
tion and is essential for cell survival [39,40].
Other proapoptotic factors such as cytochrome c, Smac/Diablo, Omi/
HtrA2 and EndoG, which may execute cell death through caspase-
dependent or caspase-independent mechanisms, are released with
mitochondrial membrane permeabilization as well as AIF. For example,
formation of the apoptosome by cytochrome c, Apaf-1, and procaspase-
9 and downstream catalytic activation of caspase-3, -6, and ‐7 arewide-
ly established mechanisms of caspase-dependent cell death execution
downstream of mitochondrial damage in many cells, including cancer
cells. Here, we detected caspase-3 activation downstream of Bid,
suggesting that this pathway may also play a role in ovarian cancer
cell death in the present model (Fig. 1c). Caspase-3 inhibition alone,
however, did not prevent IFN-α-induced cell death [14]. In addition, al-
though our data strongly suggest a major role for caspase-independent
cell death downstream of mitochondrial membrane permeabilization,
apoptosome inhibition did not prevent IFN-α-induced cell death either
(Fig. 4a–e). The release of AIF frommitochondria and its translocation to
the nucleus is oneof the events observed inOVCAR3 cells after exposure
to IFN-α2a. Using Western blot analysis and immunoﬂuoresence
staining, we showed mitochondrial release of AIF and translocation to
the nucleus, which occurred after the onset of IFN-α2a exposure. Al-
though cytochrome c was released from mitochondria, Bid inhibitor
BI-6C9 did not prevent the release of cytochrome c from mitochondria.
On the other hand, EndoG was not released after IFN-α2a exposure
(Fig. 6a–d). AIF translocation into the nucleus released from the mito-
chondria exposes the role of AIF downstream of mitochondrial demise
tomediate cell death independent of other established executionmech-
anisms of intrinsic cell death pathways, such as apoptosome formation
and activation of caspase-3. Furthermore, AIF siRNA signiﬁcantlyattenuated IFN-α2a induced cell death in OVCAR3 cells, whereas cyto-
chrome c or EndoG-RNAi did not (Fig. 5a–d), clearly demonstrating
that Bid cytotoxicity is predominantly mediated by mitochondrial AIF
release and hence caspase-independent cell death pathways.
In summary, our present study demonstrates that IFN‐α2a in-
duced apoptosis is mediated via the mitochondria-associated path-
way which is Bid regulated, followed by AIF release that involves
Bak activation and translocation to mitochondria in ovarian cancer
cells, OVCAR3. Further studies using different types of cancer cells,
will help to clarify the signaling events underlying the induction of
apoptosis by IFN-α, and thereby provide insight for the development
of improved ways to use IFN-α in the treatment of cancer and to iden-
tify new targets for cancer therapy.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2012.05.031.
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